Literature DB >> 28675685

Challenges and difficulties in pathological diagnosis of autoimmune hepatitis.

Kenichi Harada1, Nguyen Canh Hiep1, Hiromasa Ohira2.   

Abstract

Autoimmune hepatitis (AIH) with acute presentation is widely recognized as a distinct clinical entity, and its clinicopathology has been extensively studied. In most cases, AIH with acute presentation is merely acute exacerbation of classical chronic AIH, but pure acute-onset AIH without previous symptoms of chronic liver disease is also encountered. Rapid diagnosis and initiation of immunosuppressive treatment are necessary for both acute exacerbation and acute-onset to prevent fatal liver failure. The diagnostic criteria commonly used for classical AIH are generally applicable to acute exacerbation, but acute-onset AIH may present with additional pathological features. These features include an acute hepatitis phase characterized by centrilobular necrosis. However, centrilobular necrosis is also a feature of drug-induced liver injury, and there are no known histological characteristics exclusive to acute-onset AIH. Moreover, the possibilities of drug-induced AIH and immune-mediated drug-induced liver injury make diagnosis even more difficult. At present, liver biopsy is mandatory for the diagnosis of AIH with acute presentation, but careful consideration of all clinicopathological signs is necessary for differential diagnosis.
© 2017 The Japan Society of Hepatology.

Entities:  

Keywords:  acute presentation; autoimmune hepatitis; centrilobular necrosis; pathology

Year:  2017        PMID: 28675685     DOI: 10.1111/hepr.12931

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  7 in total

Review 1.  Methane Medicine: A Rising Star Gas with Powerful Anti-Inflammation, Antioxidant, and Antiapoptosis Properties.

Authors:  Yifan Jia; Zeyu Li; Chang Liu; Jingyao Zhang
Journal:  Oxid Med Cell Longev       Date:  2018-03-18       Impact factor: 6.543

Review 2.  Autoimmune hepatitis, fatty liver, and Fukushima.

Authors:  Atsushi Takahashi; Hiromasa Ohira
Journal:  Fukushima J Med Sci       Date:  2019-07-03

3.  Growth differentiation factor 15 as a novel diagnostic and therapeutic marker for autoimmune hepatitis.

Authors:  Teruko Arinaga-Hino; Tatsuya Ide; Jun Akiba; Hiroyuki Suzuki; Reiichiro Kuwahara; Keisuke Amano; Toshihiro Kawaguchi; Tomoya Sano; Eisuke Inoue; Hironori Koga; Keiichi Mitsuyama; Yasutoshi Koga; Takuji Torimura
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

4.  The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis.

Authors:  Guiqiang Wang; Atsushi Tanaka; Hong Zhao; Jidong Jia; Xiong Ma; Kenichi Harada; Fu-Sheng Wang; Lai Wei; Qixia Wang; Ying Sun; Yuan Hong; Huiying Rao; Cumali Efe; George Lau; Diana Payawal; Rino Gani; Keith Lindor; Wasim Jafri; Masao Omata; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-05-04       Impact factor: 6.047

5.  Interleukin-33/ST2-Mediated Inflammation Plays a Critical Role in the Pathogenesis and Severity of Type I Autoimmune Hepatitis.

Authors:  Kazumichi Abe; Atsushi Takahashi; Masashi Fujita; Manabu Hayashi; Ken Okai; Yoshihiro Nozawa; Hiromasa Ohira
Journal:  Hepatol Commun       Date:  2019-02-25

6.  Centrilobular zonal necrosis is a unique subtype of autoimmune hepatitis: A cohort study.

Authors:  Kaoru Ueda; Yoshio Aizawa; Chika Kinoshita; Tomohisa Nagano; Jinya Ishida; Chisato Saeki; Tsunekazu Oikawa; Toru Harada; Atsushi Hokari; Masayuki Saruta
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817

7.  Increasing incidence of acute autoimmune hepatitis: a nationwide survey in Japan.

Authors:  Atsushi Takahashi; Hiromasa Ohira; Kazumichi Abe; Mikio Zeniya; Masanori Abe; Teruko Arinaga-Hino; Takuji Torimura; Kaname Yoshizawa; Akinobu Takaki; Jong-Hon Kang; Yoshiyuki Suzuki; Nobuhiro Nakamoto; Ayano Inui; Atsushi Tanaka; Hajime Takikawa
Journal:  Sci Rep       Date:  2020-08-28       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.